Scorpius Holdings, Inc. (SCPX)
USD 0.29
(-0.87%)
USD 0.29
(-0.87%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.99 Million USD | 16.95% |
| 2022 | 5.98 Million USD | 183.08% |
| 2021 | 2.11 Million USD | -28.33% |
| 2020 | 2.94 Million USD | -3.32% |
| 2019 | 3.04 Million USD | -47.37% |
| 2018 | 5.79 Million USD | 281.19% |
| 2017 | 1.51 Million USD | 344.89% |
| 2016 | 341.64 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.51 Million USD | -27.52% |
| 2024 Q2 | 759.94 Thousand USD | -78.37% |
| 2023 Q2 | 657.77 Thousand USD | -14.12% |
| 2023 Q3 | 723.12 Thousand USD | 9.93% |
| 2023 FY | 6.99 Million USD | 16.95% |
| 2023 Q1 | 765.9 Thousand USD | 858.37% |
| 2023 Q4 | 4.84 Million USD | 570.43% |
| 2022 Q2 | 50.98 Thousand USD | -76.0% |
| 2022 FY | 5.98 Million USD | 183.08% |
| 2022 Q4 | 79.91 Thousand USD | -98.68% |
| 2022 Q3 | 6.03 Million USD | 11747.26% |
| 2022 Q1 | 212.41 Thousand USD | -65.35% |
| 2021 Q1 | 538.64 Thousand USD | 0.0% |
| 2021 FY | 2.11 Million USD | -28.33% |
| 2021 Q4 | 613.1 Thousand USD | 22.24% |
| 2021 Q3 | 501.56 Thousand USD | 9.16% |
| 2021 Q2 | 459.49 Thousand USD | -14.69% |
| 2020 FY | 2.94 Million USD | -3.32% |
| 2019 FY | 3.04 Million USD | -47.37% |
| 2018 FY | 5.79 Million USD | 281.19% |
| 2017 FY | 1.51 Million USD | 344.89% |
| 2016 FY | 341.64 Thousand USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | -3362.791% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 4.52 Million USD | -54.446% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | -8535.602% |
| Azitra, Inc. | 686 Thousand USD | -919.656% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | -841.432% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| iBio, Inc. | 225 Thousand USD | -3008.817% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 21.802% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | -538.215% |
| Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | -10554.417% |
| NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 52.5% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 37.65 Thousand USD | -18477.107% |
| BiomX Inc. | -357 Thousand USD | 2059.338% |
| BiomX Inc. | -357 Thousand USD | 2059.338% |
| Protalix BioTherapeutics, Inc. | 65.49 Million USD | 89.32% |
| Palatin Technologies, Inc. | 4.49 Million USD | -55.784% |